Sanofi-Aventis to pay up to $560 million for single product TargeGen

Sanofi-Aventis is to acquire the privately held US biopharmaceutical firm TargeGen for $75 million up front and additional milestone payments related to the development of its lead product, TG 101348, which could see the deal valued at a total of $560 million.